Groulx v. Takeda Pharmaceutical Company

CourtDistrict Court, E.D. Michigan
DecidedFebruary 6, 2025
Docket1:24-cv-12000
StatusUnknown

This text of Groulx v. Takeda Pharmaceutical Company (Groulx v. Takeda Pharmaceutical Company) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Groulx v. Takeda Pharmaceutical Company, (E.D. Mich. 2025).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN NORTHERN DIVISION

PATRICK JOSEPH GROULX,

Plaintiff, Case No. 1:24-cv-12000

v. Honorable Thomas L. Ludington United States District Judge TAKEDA PHARMACEUTICAL COMPANY, et al. Honorable Patricia T. Morris United States Magistrate Judge Defendants. _________________________________________/ OPINION AND ORDER (1) OVERRULING OBJECTIONS; (2) ADOPTING REPORT AND RECOMMENDATION IN PART; (3) DISMISSING CASE FOR FRIVOLITY AND FAILURE TO STATE A CLAIM; AND (4) ENJOINING PLAINTIFF FROM FURTHER FILINGS WITHOUT FIRST OBTAINING LEAVE

Plaintiff Patrick Joseph Groulx alleges that BioLife Plasma Services, LP unlawfully took too much of his plasma throughout eight blood donations in January and February 2023. But Plaintiff’s claims are not cognizable and Plaintiff has not shown a sufficiently concrete and particularized injury to satisfy Article III standing. So because Plaintiff proceeds in forma pauperis, Magistrate Judge Patricia T. Morris issued a report (R&R) recommending this Court sua sponte dismiss Plaintiff’s Complaint for frivolity and failure to state a claim under 28 U.S.C. § 1915(e)(2)(B). But this is not the first time Plaintiff has filed a frivolous case. Indeed, Plaintiff has filed 14 other lawsuits in this District since 2019. One remains pending. One was dismissed on the merits. One was dismissed for failure to prosecute. One was dismissed under the Prisoner Litigation Reform Act’s “three-strikes rule.” The remaining nine were dismissed for frivolity and failure to state a claim. Plaintiff’s prior cases have sued defendants ranging from the Saginaw County Road Commission to the People’s Republic of China. And his cases have included factual allegations involving herbicide exposure, cannabis TikToks, false medical records, product safety labels, blood draws, ditch digging, and railroad-track laying. Given this history of frivolous—and often duplicative—litigation, the R&R recommended that this Court enjoin Plaintiff from filing further complaints in this District without first seeking and obtaining leave.

Plaintiff filed six objections to the R&R. But, as explained below, all are improper or lack merit. The R&R will therefore be adopted in large part. This Court will dismiss Plaintiff’s Complaint and enjoin Plaintiff from further filings without first obtaining leave. This Court modifies the R&R only to the extent it limited Plaintiff’s future requests for leave to a “single page,” and accordingly will allow Plaintiff to request leave to file future complaints by either filing a copy of the proposed complaint or a licensed lawyer’s certification that the proposed complaint is filed in good faith or is not frivolous. I. On July 30, 2024, Plaintiff Patrick Joseph Groulx filed a pro se Complaint alleging BioLife Plasma Services, LP (“BioLife”) unlawfully “took over 880ml of plasma” from him on six separate

occasions in January 2023, and on two additional occasions in February 2023 when Plaintiff was attempting to donate his blood at a center in Flint, Michigan.1 ECF No. 1 at PageID.4. Plaintiff does not allege any direct injuries, and instead maintains that the excess plasma draws could have endangered his health because “[t]aking too much plasma can lead to” dehydration, fatigue, dizziness, and other similar consequences. Id. at PageID.5 (“Plaintiff believes that taking over

1 Plaintiff names numerous Defendants in his pro se Complaint, in an apparent attempt to sue the correct legal entity for Defendant BioLife Plasma Services, LP. See ECF No. 1 at PageID.1. Plaintiff alleges that Takeda Pharmaceutical Company and the Baxter Healthcare Corporation are the “parents” of BioLife, id. at PageID.4, and accordingly sues Takeda, Baxter, and numerous of their apparent corporate affiliates. See id. at PageID.1. For the purposes of this Opinion, all Defendants will be referred to as “BioLife.” 880ml of plasma from a person is wrong because it can put the person’s health at risk.”). Yet Plaintiff collectively seeks nearly $90,000,000,000 in damages. Id. On August 6, 2024, the undersigned referred all pretrial matters to Magistrate Judge Patricia T. Morris. ECF No. 4. That same day, Judge Morris granted Plaintiff’s application to

proceed in forma pauperis (IFP). ECF No. 5. On August 21, 2024, Judge Morris issued a twofold report and recommendation (R&R). ECF No. 6. First, Judge Morris recommended this Court sua sponte dismiss Plaintiff’s Complaint for frivolity and failure to state a claim under the Prisoner Litigation Reform Act’s (PLRA’s) screening requirements, 28 U.S.C. § 1915(e)(2)(B), which apply to complaints filed by non- prisoners who proceed IFP. Id. at PageID.44–48. Judge Morris explained that “plasmapheresis, [the] process through which plasma is extracted from the blood of human donors,” is governed by the Food, Drug, and Cosmetics Act of 1938 (the “FDCA”). Id. at PageID.44–45. And although Plaintiff contends that the FDCA caps a single collection of plasma at 880ml, Judge Morris concluded Plaintiff’s claim is not cognizable because “individuals cannot enforce the FDCA or its

corresponding regulations through private, civil actions.” Id. at PageID.46 (collecting cases). To the extent Plaintiff’s liberally construed pro se Complaint also asserted a negligence—or any other—claim, Judge Morris concluded such claim should be dismissed for lack of Article III standing, because “simply being put at a ‘risk’ of illness”—Plaintiff’s alleged injury—is insufficiently concrete. Id. at PageID.47. Second, Judge Morris recommended that this Court enjoin Plaintiff from further filings without first seeking leave of the Court. Id. at PageID.48–51. Judge Morris explained: In 2019, Groulx filed a case in state court against a company he accused of negligently spraying an herbicide on a farm neighboring his home. (Groulx v. Crop Production Servs., No. 1:19-cv-12560, ECF No. 1-1 (E.D. Mich. filed August 30, 2019)). Groulx alleged that he inhaled the herbicide after it drifted onto his property and that he later experienced headaches, breathing difficulties, and erectile disfunction. (Id.) The matter was removed to this Court, and the Court later entered summary judgment against Groulx. (ECF No. 1; ECF No. 81)

Yet this was only the beginning of Groulx’s crusade. Between 2019 and 2022, Groulx filed five more cases regarding the neighboring farm’s use of herbicides.2 And during this time, he brought three other unrelated actions concerning trivial and odd disputes.3 For instance, he sued the social media platform, Tik Tok, for deleting an account on which he posted videos demonstrating “how to grow marijuana.” (Groulx v. People’s Republic of China, 1:22-cv-12295, ECF No. 1, PageID.3 (E.D. Mich. Sept. 27, 2022). In another case, Groulx sued his municipality for mowing a ditch on his property that he believed to contain endangered plants and insects. (Groulx v. Saginaw Cnty. Road Comm’n, 1:22-cv- 12049, ECF No. 1, PageID.2–3 (E.D. Mich. Aug. 29, 2022)).

Each of these seven complaints are difficult to follow, riddled with bizarre statements, and smacking of paranoid delusions. Not surprisingly, they have all been dismissed on the Court’s own motion for lack or jurisdiction or Groulx’s failure to state a claim.4 Despite this, Groulx still continues to inundate the Court with strange, frivolous complaints. Indeed, following a brief hiatus from his litigious endeavors, Groulx returned to the Court this [past] summer to file eight more complaints between July and August [2024].5 Like his prior actions, these new complaints are frivolous and draw the court’s attention from other plaintiffs with legitimate disputes.

Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Robert Dale Murr v. United States
200 F.3d 895 (Sixth Circuit, 2000)
Aldrich v. Bock
327 F. Supp. 2d 743 (E.D. Michigan, 2004)
Rittner v. Kinder
290 F. App'x 796 (Sixth Circuit, 2008)
Feathers v. Chevron U.S.A., Inc.
141 F.3d 264 (Sixth Circuit, 1998)
Landrith v. Schmidt
732 F.3d 1171 (Tenth Circuit, 2013)
Chance v. Todd
74 F. App'x 598 (Sixth Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Groulx v. Takeda Pharmaceutical Company, Counsel Stack Legal Research, https://law.counselstack.com/opinion/groulx-v-takeda-pharmaceutical-company-mied-2025.